Intermountain Health Review

Intermountain Health — Provider Profile

Overview

Intermountain Health is one of the largest non-profit health systems in the western United States, operating over 30 hospitals and hundreds of clinics across Utah, Nevada, Colorado, Montana, Wyoming, Idaho, and Kansas. Their weight management program combines in-person care with telehealth visits, offering GLP-1 prescriptions as part of a comprehensive, insurance-integrated medical weight management program.

April 2026 context: Intermountain prescribes brand-name GLP-1 medications through its endocrinology and weight management clinics. Orforglipron (Eli Lilly oral GLP-1) is not yet FDA-approved — PDUFA date April 10, 2026. Medicare GLP-1 Bridge coverage for obesity is pending. Intermountain does not prescribe compounded GLP-1 medications.

Unlike direct-to-consumer telehealth platforms, Intermountain operates as a traditional health system with insurance billing, in-person clinics, and integrated electronic health records. Patients typically access GLP-1 treatment through their primary care physician or a referral to the weight management program.

Medications Offered

• Brand Wegovy (semaglutide) — FDA-approved for chronic weight management
• Brand Zepbound (tirzepatide) — Dual GIP/GLP-1 receptor agonist
• Brand Ozempic (semaglutide) — Prescribed for type 2 diabetes patients
• Metformin — Adjunct therapy for insulin resistance

Pricing

• Insurance-based model — Costs depend on individual insurance coverage
• Copays — Typically $25-$75/month with commercial insurance

Pros

• Integrated health system with full medical records and continuity of care
• Insurance billing for both office visits and medications
• In-person clinic access across 7 western states
• Board-certified physicians with obesity medicine training
• Comprehensive lab work and metabolic monitoring included

Cons

• No telehealth-first experience — requires existing patient relationship or referral
• Brand-name medications only — no compounded or lower-cost alternatives
• Geographic limitation to western US states
• Slower onboarding compared to dedicated telehealth platforms
• Insurance pre-authorization required for GLP-1 medications